News & Updates

Show Multimedia Only

Pazopanib tolerable, improves survival in metastatic soft tissue sarcoma

27 May 2021

Treatment with pazopanib is both effective and well tolerated in good performance status patients with relapsed, advanced nonadipocytic soft tissue sarcomas, results of a multicentre retrospective study have shown.

Pazopanib tolerable, improves survival in metastatic soft tissue sarcoma

27 May 2021

Cyclophosphamide-free chemo may promote menses resumption

27 May 2021

Breast cancer patients receiving treatment with a cyclophosphamide-free chemotherapy regimen are likely to resume their menses, according to a phase III trial.

Cyclophosphamide-free chemo may promote menses resumption

27 May 2021

Fitness trackers motivate cancer survivors to exercise more

26 May 2021 by

Cancer survivors who use wearable activity trackers (WATs) tend to meet physical activity (PA) recommendations more often, according to a recent study.

Fitness trackers motivate cancer survivors to exercise more

26 May 2021

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

24 May 2021

Children treated with BRAF and MEK inhibitors are prone to cutaneous reactions, many of which result in alterations or interruptions in oncologic therapy, reports a study.

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

24 May 2021

News & Updates

Showing Oncology articles

Showing

Specialty:

Pazopanib tolerable, improves survival in metastatic soft tissue sarcoma

Pazopanib tolerable, improves survival in metastatic soft tissue sarcoma

Cyclophosphamide-free chemo may promote menses resumption

Cyclophosphamide-free chemo may promote menses resumption

Fitness trackers motivate cancer survivors to exercise more

Fitness trackers motivate cancer survivors to exercise more

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children